Zeprumetostat+Azacitadine
Phase 2Small molecule
Zeprumetostat+Azacitadine is one of 19 small molecule programs targeting Refractory. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
18
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
27 competitors in Refractory
#DrugCompanyPhaseTrials
1Nplate
AmgenPhase 3
Jakafi
IncytePhase 2
Cabometyx
Bristol-Myers SquibbPhase 2
Blincyto
AmgenPhase 1
Gecacitinib
SSuzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 2
Maat013
MMaaT Pharma
Phase 3
Tavalisse
RRigel Pharmaceuticals
Phase 1
Flomax
SanofiPreclinical
MB-CART19.1
MMiltenyi Biomedicine GmbH
Phase 2
CD19 CAR-T Cells
CChongqing Precision Biotech Co., Ltd
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zeprumetostat+Azacitadine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRuijin Hospital